Basal Cell Carcinoma
Conditions
Keywords
imiquimod, surgical excision
Brief summary
Basal cell carcinoma (BCC) is the most prevalent form of cancer among the Caucasian population. There are several subtypes of BCC with different clinical characteristics and treatment strategies. Superficial and nodular BCCs are low-risk BCC subtypes. The diagnosis and subtype of BCC can be confirmed by means of punch biopsy, but non-invasive diagnosis by means of Optical Coherence Tomography (OCT) is proven to be a non-inferior alternative diagnostic instrument. Besides, non-invasive topical treatment is recommended as valuable treatment alternative to surgical excision for low-risk BCC. Since non-invasive diagnosis and treatment for low-risk BCC is being implemented into daily practice, we want to evaluate the real-world effectiveness of different invasive and non-invasive diagnostic and treatment strategies in the management of low-risk BCC. This real-world evidence will enhance our understanding of these management strategies for low-risk BCC in daily practice.
Interventions
DRUGImiquimod Topical
Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
Sponsors
Maastricht University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients ≥18 years old * Diagnosis of low-risk BCC based on CDE with OCT confirmation or with histopathological verification in case OCT diagnosis is doubtful. * Tumors meeting the criteria for low-risk BCC * Patient is able to understand the instruction regarding the study participation and application of IMQ treatment
Exclusion criteria
* Tumor location in the H-zone of the face or hairy scalp, anogenital area * Diagnosis of recurrent BCC or previous skin cancer within 2cm of the treatment area * Strong suspicion/diagnosis of high-risk BCC subtype or other skin condition on OCT or punch biopsy * Women who are pregnant or breastfeeding * Previous allergy or intolerance to IMQ * No concurrent use any other systemic chemopreventive or immunosuppressive medication during the treatment period, 30 days before start and 3 months after the end of treatment * Limited understanding of the Dutch language and not being able to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness of imiquimod versus surgical excision | 1 year post-treatment | Treatment success, expressed as the proportion of tumor free patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse effects | During imiquimod treatment, reported by the patient | Incidence and severity of adverse effects |
| Mean treatment compliance for patients in the imiquimod group | During treatment, reported by the patient in a treatment checklist | In percentages |
| Cosmetic outcome | 1 year post-treatment | Patient-reported satisfaction with cosmetic result of treatment area, expressed as mean score on the DASS questionnaire |
| Patient treatment satisfaction | 1 year post-treatment | Patient-reported satisfaction with treatment, expressed as the proportion of patients reporting to be satisfied with their treatment on a 4-point Likert-scale. |
| Cost-effectiveness analysis | 1 year post-treatment | Cost-effectiveness will be analysed from a health-care perspective: pre-, during and post-treatment costs will be recorded and analysed and compared in both treatment groups using a cost-effectiveness analysis (CEA) |
Countries
Netherlands
Contacts
Primary ContactMyrthe MG Moermans, MD
Outcome results
None listed